CYTK
Cytokinetics, Incorporated
There isn't enough reported data to score CYTK yet.
CYTK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
CYTK's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CYTK PE Valuation
CYTK has no meaningful PE right now: it lost money over the past year.
CYTK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CYTK's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CYTK Earnings Per Share
CYTK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $47.6M | +2356% |
| Q2 2026 | $28.6M | -57% |
| Q1 2026 | $19.4M | +1126% |
| Q4 2025 | $17.8M | +4.9% |
| Q3 2025 | $1.9M | +318% |
| Q2 2025 | $66.8M | +26715% |
| Q1 2025 | $1.6M | +89% |
| Q4 2024 | $16.9M | +912% |
CYTK's revenue is recovering but still below its 2022 peak: $48M last quarter, up 2356% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -351% | +8262 points |
| Q2 2026 | -626% | -459 points |
| Q1 2026 | -949% | +8908 points |
| Q4 2025 | -1005% | -183 points |
| Q3 2025 | -8613% | +21797 points |
| Q2 2025 | -167% | +52111 points |
| Q1 2025 | -9856% | +5262 points |
| Q4 2024 | -821% | +6799 points |
CYTK's operating margin was −351% last quarter, up 8262 points from the same quarter a year ago.
CYTK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$124.7M | -$7.9M |
| Q2 2026 | -$164.2M | -$31.8M |
| Q1 2026 | -$151.4M | -$14.1M |
| Q4 2025 | -$148.3M | -$81.4M |
| Q3 2025 | -$116.9M | -$14.7M |
| Q2 2025 | -$132.4M | -$31.2M |
| Q1 2025 | -$137.3M | -$7.8M |
| Q4 2024 | -$66.9M | +$7.3M |
CYTK has burned cash in almost every quarter: −$589M over the past year, against −$453M the year before.
CYTK Total Shares
CYTK Net Leverage
CYTK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CYTK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 8.2 | Oversold |
CYTK's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
CYTK PE vs Healthcare Sector
CYTK has no meaningful PE right now: it lost money over the past year.
CYTK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.2 | 8.2% below |
| 20 week MA | $70.7 | 21% below |
| 50 week MA | $68.4 | 18% below |
| 100 week MA | $56.6 | 0.8% below |
| 200 week MA | $53.0 | 6% above |
CYTK has fallen below most of its moving averages, though it's still 6% above its 200-week average.
CYTK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $20.9 | +103% |
| 2021 | $20.9 | $44.7 | +113% |
| 2022 | $44.7 | $45.6 | +2.1% |
| 2023 | $45.6 | $83.5 | +83% |
| 2024 | $83.5 | $47.4 | -43% |
| 2025 | $47.4 | $63.1 | +33% |
| 2026 YTD | $63.1 | $56.2 | -11% |
CYTK's yearly returns have swung widely, from +113% in 2021 to −43% in 2024. It's down 11% so far in 2026.